Anika Therapeutics reported $20.81M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US $ 5276M 780M
Agenus AGEN:US $ 10.06M 551K
Anika Therapeutics ANIK:US $ 20.81M 0.16M
Flexion Therapeutics FLXN:US $ 23.2M 4.69M
Halozyme Therapeutics HALO:US $ 113.44M 42.63M
Heron Therapeutics HRTX:US $ 7.92M 2.89M
Insmed INSM:US $ 34.53M 4.16M
Integra Lifesciences IART:US $ 249.45M 25.02M
Johnson & Johnson JNJ:US $ 15725M 440M
Karyopharm Therapeutics KPTI:US $ 21.46M 864K
Ligand Pharmaceuticals LGND:US $ 54.08M 7.08M
MacroGenics MGNX:US 30.74M 13.87M
Merit Medical Systems MMSI:US $ 124.14M 12.24M
Peregrine Pharmaceuticals PPHM:US $ 11.39M 3.25M
Rigel Pharmaceuticals RIGL:US $ 26.14M 54.56M
Stryker SYK:US $ 2712M 281M
Surmodics SRDX:US $ 18.77M 12.06M
Veracyte VCYT:US $ 37.63M 13.33M
Zimmer Biomet Holdings Inc ZBH:US $ 1.45B 114.3M